Anti-Helicobacter pylori and Anti-inflammatory Properties of Eugenia uniflora L

Abstract Helicobacter pylori is a bacterium that reaches half of the world population and it's recognized as the main cause of chronic gastritis and peptic ulcer. In this study, we evaluated the anti-H. pylori, antioxidant and immunomodulatory activities of the methanolic (MeOH) extract of Eugenia uniflora leaves and chemical profile. Anti-H. pylori activity was evaluated by spectrophotometric broth microdilution technique by determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC), in addition to the evaluation of the effect on the urease enzyme. The antioxidant activity was evaluated by capturing O2 •-, HOCl e NO• radicals. The immunomodulatory effect was evaluated on the cytokines TNF-α, IL-6 and on nitric oxide through inhibition in LPS-stimulated macrophages. The chemical profile was performed by total phenolic, tannin and flavonoid contents and mass spectrometry analysis by ESI-FT-ICR MS. In the anti-H. pylori assay the extract showed MIC of 128 μg/mL, however it did not obtain MBC. The extract also showed ability to inhibit the urease enzyme about 20%. The antioxidant activity of the MeOH extract showed EC50 values of 29.77 µg/mL, 15.71 µg/mL and 442.10 µg/mL to O2 •-, HOCl and NO•, respectively. The extract also showed influence on the release of TNF-α, IL-6 and NO in LPS-stimulated macrophages, ranging from 39% to 97% inhibition. Flavonoids, phenylpropanoids, tannins, triterpenoids and carbohydrates were the major classes of compounds present in the MeOH extract as identified by (-)-ESI-FT-ICR MS. The results indicate important anti-H. pylori, antioxidant and immunomodulatory activities from Eugenia uniflora highlighting its importance in the prevention and treatment of diseases caused by H. pylori infection.

Safety assessment of omeprazole use: a review

ABSTRACT BACKGROUND: Risks regarding hospital admission due to adverse drug reactions and drug interactions from use of omeprazole have been reported. The question guiding the present review was "Which adverse events occur in patients using omeprazole in a Food and Drug Administration-approved and/or off-label manner?" It was also proposed to evaluate the safety of use of omeprazole. DESIGN AND SETTING: Qualitative narrative review with critical evaluation, in a public university. METHODS: The PubMed, SCOPUS, LILACS, SciELO, EMBASE and EBSCO databases were searched on July 31, 2018. Studies evaluating adverse events were screened. RESULTS: 72 articles were included, among which 58 reported on adverse drug events (47, adverse drug reactions; 5, drug interactions; and 6, situations of ineffectiveness). 28 adverse drug reactions not described in compendia and drug leaflets were described in these studies: myocardial infarction (6); stroke (2); spontaneous abortion (1); proliferative changes (1); chills (1); heart failure (1); thrombosis (2); and dementia (1), among others. Severe adverse reactions, for instance cardiac problems, Steven-Johnson syndrome and proliferative changes, were identified. The antiplatelet effects of drugs such as clopidogrel, in patients who underwent heart-related surgery, increased the risk of developing cardiac problems, such as cardiovascular death, myocardial infarction and stroke. In newly transplanted patients, decreased absorption of mycophenolate mofetil occurred, thus leading to rejection of transplanted organs. CONCLUSION: Use of omeprazole should be monitored primarily in patients with heart disorders using antiplatelet agents concomitantly, and in newly transplanted patients using mycophenolic acid, in order to avoid serious adverse reactions.

Píloro doble: de lo cotidiano a lo extraordinario: reporte de caso y revisión de la literatura / Double pylorus: from the everything to the extraordinary: case report and literature review

Antecedentes: El píloro doble constituye un hallazgo endoscópico extremadamente raro, siendo más frecuente en pacientes que padecen enfermedad ulcerosa péptica. Corresponde a una comunicación anormal entre el antro gástrico y el bulbo duodenal, que puede llegar a requerir tratamiento quirúrgico. Caso clínico: Mujer de 86 años de edad con antecedentes de diabetes mellitus tipo 2, hipertensión arterial, así como ingesta crónica de AINE, portadora de enfermedad ácido-péptica de larga evolución con poca respuesta al manejo médico con bloqueadores H2, la cual presenta sangrado de tubo digestivo durante 5 días caracterizado por hematemesis y melena, así como pirosis, náuseas, sin pérdida ponderal; por este motivo se realiza endoscopia digestiva alta la cual reporta como hallazgos: gastritis erosiva crónica activa secundaria a AINE y asociada a Helicobacter pylori, así como píloro doble adquirido secundario a enfermedad ácido-péptica, sin evidencia de tumores u otras lesiones asociadas. Se inicia esquema de erradicación para H. pylori con amoxicilina y claritromicina durante 14 días, asociados a inhibidor de bomba de protones durante 6-8 semanas con buena respuesta al manejo médico. Discusión: El píloro doble adquirido es una rara complicación de úlcera péptica que puede ser asociada a otras enfermedades, AINE y a la colonización por H. pylori, por lo tanto el adecuado tratamiento consistirá en la corrección de esos factores.

Background: The double pylorus is an extremely rare endoscopic finding, being more frequent in patients suffering from peptic ulcer disease. It corresponds to an abnormal communication between the gastric antrum and the duodenal bulb, which may require surgical treatment. Clinical case: A 86-year-old woman with a history of type 2 diabetes mellitus, hypertension and chronic NSAID intake, a carrier of long-term peptic acid disease with poor response to medical management with H2 blockers. This presents digestive tube bleeding for 5 days characterized by hematemesis and melena, as well as heartburn, nausea, without weight loss, reason why high digestive endoscopy is performed, which reports as findings: active chronic erosive gastritis secondary to NSAIDs and associated with Helicobacter pylori, as well as acquired double pylorus secondary to peptic acid disease, without evidence of tumors or other associated lesions. Eradication scheme begins for H. pylori with amoxicillin and clarithromycin for 14 days, associated with a proton pump inhibitor for 6-8 weeks with good response to medical management. Discussion: The acquired double pylorus is a rare complication of peptic ulcer disease that can be associated with other diseases, NSAIDs and colonization by H. pylori, therefore the appropriate treatment will consist in the correction of these factors.

To evaluate of the effect of adding licorice to the standard treatment regimen of Helicobacter pylori

ABSTRACT Objective: The aim of this study was to evaluate the effect of licorice in H. pylori eradication in patients suffering from dyspepsia either with peptic ulcer disease (PUD) or non-ulcer dyspepsia (NUD) in comparison to the clarithromycin-based standard triple regimen. Methods: In this randomized controlled clinical trial, 120 patients who had positive rapid urease test were included and assigned to two treatment groups: control group that received a clarithromycin-based triple regimen, and study group that received licorice in addition to the clarithromycin-based regimen for two weeks. H. pylori eradication was assessed six weeks after therapy. Data was analyzed by chi-square and t-test with SPSS 16 software. Results: Mean ages and SD were 38.8 ± 10.9 and 40.1 ± 10.4 for the study and control groups, respectively, statistically similar. Peptic ulcer was found in 30% of both groups. Response to treatment was 83.3% and 62.5% in the study and control groups, respectively. This difference was statistically significant. Conclusion: Addition of licorice to the triple clarithromycin-based regimen increases H. pylori eradication, especially in the presence of peptic ulcer disease.

Recurrence rate of helicobacter pylori in patients with peptic ulcer five years or more after successful eradication / Taxa de reinfecção por Helicobacter pylori em pacientes com úlcera péptica cinco anos após erradicação

ABSTRACT Background Infection with Helicobacter pylori is highly prevalent worldwide, especially in developing countries. Its presence in the gastroduodenal mucosa is related with development of peptic ulcer and other illnesses. The eradication of H. pylori improves mucosal histology in patients with peptic ulcers. Objective This study was aimed to verify if H. pylori recurrence occurs five years or more after confirmed eradication in patients with peptic ulcer. Moreover, we sought to determine the recurrence rate. Methods Retrospective and longitudinal, this study was based on a sample of 201 patients from western Paraná, Brazil. The patients were diagnosed with peptic ulcer disease, in the period of 1990-2000, and followed for five years or more after successful H. pylori eradication. Patients with early recurrence - prior to five years after eradication - were excluded from the sample. Results During an average follow-up of 8 years, 180 patients (89.55%) remained negative, and 21 (10.45%) became positive for H. pylori infection. New ulcers appeared in two-thirds of the patients with H. pylori recurrence. Conclusion The recurrence of H. pylori in patients with peptic ulcer can occur in the long-term - even if the infection had been successfully eradicated and the patients had remained free of recurrence in the first years of follow-up.

RESUMO Contexto A infecção por Helicobacter pylori é altamente prevalente no mundo, especialmente nos países em desenvolvimento, e sua presença na mucosa gastroduodenal está associada com o desenvolvimento de úlcera péptica e outras patologias. A erradicação do H. pylori melhora a histologia da mucosa em pacientes com úlcera péptica. Objetivo Determinar se a recorrência da infecção por H. pylori ocorre cinco anos ou mais após a erradicação confirmada em pacientes com úlcera péptica. Além disso, buscou-se determinar a taxa de recorrência. Método Retrospectivo e longitudinal, o estudo foi baseado em uma amostra de 201 pacientes oriundos da região Oeste do Paraná, Brasil. Os pacientes foram diagnosticados com úlcera gástrica e/ou duodenal, no período de 1990-2000, e foram seguidos por pelo menos cinco anos após a erradicação com sucesso do H. pylori. Pacientes com recorrência precoce - nos primeiros cinco anos após a erradicação - foram excluídos da amostra. Resultados - Após um tempo médio de seguimento de oito anos, 180 pacientes (89,55%) permaneceram negativos e 21 (10,45%) tornaram-se positivos para a presença de H. pylori. Novas úlceras apareceram em dois terços dos pacientes com recorrência da bactéria. Conclusão A recorrência da infecção por H. pylori ocorre em longo prazo - mesmo se a infecção tiver sido erradicada com sucesso e os pacientes permanecido livres de recorrência nos primeiros cinco anos de seguimento.

An overview of malaria transmission from the perspective of Amazon Anopheles vectors

In the Americas, areas with a high risk of malaria transmission are mainly located in the Amazon Forest, which extends across nine countries. One keystone step to understanding the Plasmodium life cycle in Anopheles species from the Amazon Region is to obtain experimentally infected mosquito vectors. Several attempts to colonise Ano- pheles species have been conducted, but with only short-lived success or no success at all. In this review, we review the literature on malaria transmission from the perspective of its Amazon vectors. Currently, it is possible to develop experimental Plasmodium vivax infection of the colonised and field-captured vectors in laboratories located close to Amazonian endemic areas. We are also reviewing studies related to the immune response to P. vivax infection of Anopheles aquasalis, a coastal mosquito species. Finally, we discuss the importance of the modulation of Plasmodium infection by the vector microbiota and also consider the anopheline genomes. The establishment of experimental mosquito infections with Plasmodium falciparum, Plasmodium yoelii and Plasmodium berghei parasites that could provide interesting models for studying malaria in the Amazonian scenario is important. Understanding the molecular mechanisms involved in the development of the parasites in New World vectors is crucial in order to better determine the interaction process and vectorial competence.

Uso inadecuado del bloqueador H2 ranitidina en pacientes hospitalizados en el servicio de emergencia de adultos de un hospital general de EsSalud / Inappropriate use of H2 blocker ranitidine in patients hospitalized in the adult emergency service observation room in an EsSalud general hospital

La terapia profiláctica para úlcera de estrés es una práctica habitual en los servicios de emergencia, siendo muchas veces inadecuada. Objetivo: Determinar si existe uso inadecuado del bloqueador H2 ranitidina, en un servicio de emergencia de adultos. Diseño: Estudio observacional transversal. Lugar: Servicio de Emergencia, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Perú. Participantes: Pacientes de 14 años o más. Intervenciones: Se revisó las historias clínicas de 422 pacientes ingresados a las salas de observación de emergencia, entre los meses de enero y marzo de 2011. Usando prueba correlacional, los diagnósticos fueron confrontados con la pertinencia del uso de la ranitidina según las guías clínicas, en relación fundamentalmente a la profilaxis de úlcera de estrés. Principales medidas de resultados: Detectar el uso inadecuado de ranitidina mediante ASHP Report Therapeutic Guidelines on Stress Ulcer. Resultados: Del total, 49,8 por ciento (210) fueron varones y 50,2 por ciento (212) mujer. La edad promedio fue 62,2 años (DS 18,9). Los antecedentes más frecuentes fueron hipertensión arterial (24,9 por ciento) y, por sistemas, el cardiovascular (32,5 por ciento). El diagnóstico de ingreso más frecuente fue el síndrome doloroso abdominal (13,3 por ciento) y, por sistema, el cardiovascular (18,6 por ciento). De las personas atendidas, 78,9 por ciento no tenía recomendación de prescripción de ranitidina según los diagnósticos consignados. La ranitidina fue administrada a 63,5 por ciento (268) de los pacientes ingresados. El 72 por ciento (193) de las prescripciones de ranitidina no era recomendada según las guías clínicas, con una medida de concordancia índice de kappa de 0,151 o grado de acuerdo insignificante entre las recomendaciones de las guías y las prescripciones realizadas. De los pacientes sin recomendación, 59,9 por ciento recibió prescripción inadecuada de ranitidina por la especialidad de medicina de emergencia, de cirugía...

Objective: To determine H2 blocker ranitidine misuse in an adult emergency service observation room. Design: Observational crosssectional study. Setting: Emergency Service, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Peru. Participants: Patients 14 year-old or older. Interventions: Clinical charts of 422 patients admitted to the emergency observation rooms between January and March 2011 were reviewed. Diagnosis was confronted with pertinence of ranitidine use according to clinical guidelines of stress ulcer prophylaxis. Main outcome measures: Inadequate use of ranitidine by the ASHP Report Therapeutic Guidelines on Stress Ulcer. Results: Patients were male in 49.8 per cent (210) and female in 50.2 per cent (212), 62.2 year-old average. Most frequent antecedent was hypertension in 24.9 per cent and cardiovascular as classified by systems in 32.4 per cent. Most frequent admission diagnosis was abdominal pain syndrome in 13.3 per cent, and cardiovascular by systems in 18.6 per cent. From patients admitted 78.9 per cent had no recommendation of ranitidine prescription according to appropriate diagnosis. Ranitidine was administered to 63.5 per cent (268) of patients admitted to observation; 72 per cent (193) of ranitidine prescriptions were not recommended according to current clinical guidelines; kappa index 0.151 showed insignificant agreement. Of patients admitted with no recommendation of ranitidine 59.9 per cent received ranitidine by the emergency medicine specialty, 63.8 per cent by surgery and 11.8 per cent by traumatology. Conclusions: There was ranitidine prescription misuse at Rebagliati Hospital EsSalud emergency observation room by the emergency medicine, surgery and traumatology specialties...

Comparison of oral and intravenous proton pump inhibitor in patients with high risk bleeding peptic ulcers

To compare the efficacy of oral omeprazole vs intravenous omeprazole in decreasing risk of re-bleeding in peptic ulcer patients. This prospective, randomized, controlled clinical trial was conducted at Ghulam Mohammad Mahar Medical College Hospital, Sukkur, Pakistan from January 2010 to December 2011. One hindered and six patients with high risk peptic ulcer were randomized to receive either oral omeprazole [80mg BID for 3 days] or IV omeprazole [80mg bolus and 8mg/hour infusion for 3 days] followed by omeprazole [20mg each day for 30 days]. All patients underwent upper endoscopy and endoscopic therapy within 24 hours. Seventeen patients were excluded from the study. Forty four patients were randomly allocated into oral omeprazole group and 41 to IV omeprazole group. Both groups were similar for factors affecting the outcome. Bleeding reoccurred in five patients of oral omeprazole group and four patients in IV omeprazole group [11.4% vs 9.8%]. The mean hospital stay and blood transfusion were not different in both groups. Oral omeprazole and IV omeprazole had equal effects on prevention of re-bleeding after endoscopic therapy in patients with high risk bleeding peptic ulcers

Helicobacter pylori infection in India from a western perspective.

Helicobacter pylori is a common bacterial infectious disease whose manifestations predominately affect the gastrointestinal tract. India is the prototypical developing country as far as H. pylori infection is concerned and more than 20 million Indians are estimated to suffer from peptic ulcer disease. Considering the high level of medical research and of the pharmaceutical industry, one would expect that India would be the source of much needed information regarding new therapies and approaches that remain effective in the presence of antimicrobial resistance, new methods to reliably prevent reinfection, and the development of therapeutic and preventive vaccines. Here we discuss H. pylori as a problem in India with an emphasis on H. pylori infection as a serious transmissible infectious disease. We discuss the pros and cons of eradication of H. pylori from the entire population and come down on the side of eradication. The available data from India regarding antimicrobial use and resistance as well as the effectiveness of various treatments are discussed. Rigorous ongoing studies to provide current regional antibiotic resistance patterns coupled with data concerning the success rate with different treatment regimens are needed to guide therapy. A systematic approach to identify reliably effective (e.g., 90% or greater treatment success) cost-effective regimens is suggested as well as details of regimens likely to be effective in India. H. pylori is just one of the health care problems faced in India, but one where all the resources are on hand to understand and solve it.

Capacidade aquisitiva e disponibilidade de medicamentos para doenças crônicas no setor público / Affordability and availability of drugs for treatment of chronic diseases in the public health care system

OBJETIVO: Avaliar a capacidade aquisitiva do trabalhador para pagar medicamentos utilizados no tratamento de doenças crônicas e a disponibilidade desses medicamentos na forma de referência, similar ou genérica para fornecimento gratuito no setor público. MÉTODOS: Utilizou-se metodologia preconizada pela Organização Mundial da Saúde (OMS) e Health Action International (HAI) para coleta padronizada de informações sobre preços de venda no setor privado e disponibilidade no setor público de medicamentos em seis cidades do Rio Grande do Sul, Brasil. A coleta de dados ocorreu de novembro de 2008 a janeiro de 2009. A capacidade aquisitiva foi estimada como o número de dias do salário que um trabalhador com rendimento de 1 salário mínimo nacional necessita trabalhar para adquirir, em uma farmácia privada, a quantidade necessária de medicamento para 1 mês de tratamento. A disponibilidade foi avaliada verificando-se a presença dos medicamentos nas farmácias do setor público. RESULTADOS: A pesquisa incluiu 22 estabelecimentos públicos e 30 farmácias privadas. Dos 21 medicamentos utilizados no tratamento de sete doenças crônicas, apenas nove eram disponibilizados gratuitamente nos seis municípios pesquisados. O percentual médio da disponibilidade variou de 83,3 por cento (São Leopoldo) a 97,6 por cento (Caxias do Sul). A capacidade aquisitiva variou de 0,4 a 10,5 dias de salário para medicamentos de referência; de 0,2 a 8,4 dias de salário para medicamentos similares; e de 0,3 a 3,8 dias de salário para medicamentos genéricos. CONCLUSÕES: A disponibilidade geral dos medicamentos pesquisados foi superior aos 80 por cento recomendados pela OMS; porém, alguns tratamentos não estavam disponíveis, ou apresentaram uma disponibilidade limitada no setor público. A capacidade aquisitiva dos trabalhadores nos municípios estudados indicou um comprometimento de dias do salário que pode afetar a continuidade dos tratamentos com medicamentos para doenças crônicas.

OBJECTIVE: To assess the affordability by workers of drugs used for treatment of chronic diseases, as well as the availability of the reference, similar, or generic forms of these drugs in the public health care system. METHODS: We employed the methodology recommended by the World Health Organization (WHO) and Health Action International (HAI) for the standardized collection of information on selling prices in the private sector and availability in the public health care system of drugs in six cities in the state of Rio Grande do Sul, Brazil. Data were collected from November 2008 to January 2009. Affordability was estimated as the number of salary days required for a worker receiving the national minimum wage to buy, in a private pharmacy, the amount of medication required for one month of treatment. Availability was assessed by the presence of these drugs in public health care system facilities. RESULTS: Twenty-two public facilities and 30 private pharmacies were studied. Of 21 drugs used for the treatment of seven chronic disorders, only nine were available free of charge in the six cities. Mean availability ranged from 83.3 percent (São Leopoldo) to 97.6 percent (Caxias do Sul). Affordability ranged from 0.4 to 10.5 salary days for reference drugs, 0.2 to 8.4 salary days for similar drugs, and 0.3 to 3.8 salary days for generic drugs. CONCLUSIONS: The overall availability of the drugs surveyed was higher than the 80 percent recommended by WHO. However, some treatments were not available, or had limited availability in the public system. Concerning affordability, the number of salary days required to buy these drugs may affect the continuation of drug treatments for chronic diseases.

Effect of Zinc Salts on Acid Secretion and Peptic Ulceration in Albino Rats.

The present study was carried out to see the effect of two zinc salts i.e zinc sulphate and zinc chloride on gastric ulcers induced by stress, pylorus ligation and aspirin in albino rats. The rats were divided into two main groups (zinc sulphate 30, 60, 90 mg/kg i.p and zinc chloride 10 and 20mg/kg i.p). They were further sub-divided into three sub-groups dependant on ulcer model i.e stress, pylorus ligation and aspirin induced ulcers. It was found that zinc sulphate and zinc chloride had a dose dependant reduction in ulcer index in all three models of gastric ulceration. Also, both the salts had anti acid secretory effect, raised pH of gastric secretion and reduced total acidity significantly. Thus zinc salts prevent gastric ulceration. Probably this effect is mediated by anti acid secretory action.

Effect of Acid Pump Antagonist (Revaprazan, Revanex(R)) on the Result of 13C Urea Breath Test in the Patients with Helicobacter pylori Associated Peptic Ulcer Disease / 대한소화기학회지

No abstract available.

Effect of Acid Pump Antagonist (Revaprazan, Revanex(R)) on Result of 13C Urea Breath Test in Patients with Helicobacter pylori Associated Peptic Ulcer Disease / 대한소화기학회지

BACKGROUND/AIMS: Revaprazan (Revanex(R)) is a novel proton pump inhibitor (PPI) that has a somewhat different effect on proton pump compared with the other PPI's, also (called as 'acid pump antagonist'). We aimed to examine the false negative rate of 13C-urea breath test (UBT) in the patients with Helicobacter pylori (H. pylori) associated peptic ulcer disease who were treated with revaprazan and evaluate the anti-urease activity of revaprazan. METHODS: Total 55 patients were enrolled in this study. They received EGD examination between January 2009 and December 2009 and diagnosed histologically as H. pylori associated peptic ulcer disease. All patients took revaprazan only. Three patients were excluded because of underlying chronic disease and inappropriate breath sampling. The remaining 52 patients had UBT at 0, 2 and 4 weeks of revaprazan use. After 2 weeks of the cessation of revaprazan, they had the fourth UBT. RESULTS: At 2 and 4 weeks, the false negative rates of UBT were 5.8% and 23.1%, respectively (p=0.05). After 2 weeks of the cessation, the cases of the false negative result were five. Four out of five patients had prolonged negative results on two or three successive tests, and baseline 13C difference value did not predict the false negative results. CONCLUSIONS: False negative results of UBT were common and increased with prolonged use of acid pump antagonist. As PPI, it had also anti-urease activity and most patients (47/52, 90.4%) reverted to positive results by 2 weeks after the cessation of taking the medication.

Comparison of oral and intravenous proton pump inhibitor on patients with high risk bleeding peptic ulcers: a prospective, randomized, controlled clinical trial

Proton pump inhibitors [PPIs] decrease the rate of rebleeding following endoscopic hemostatic therapy in patients with bleeding peptic ulcers. This study compares the efficacy of oral omeprazole vs intravenous pantoprazole in decrease of rebleeding of peptic ulcer patients. One hundred and six patients with high risk peptic ulcer were randomized to receive either oral omeprazole [80 mg BID for 3 days] or IV pantoprazole [80 mg bolus and 8 mg/hour infusion for 3 days] followed by omeprazole [20 mg each day for 30 days]. All patients underwent upper endoscopy and endoscopic therapy within 24 hours. Seventeen patients were excluded from the study. Forty four patients were randomly allocated into omeprazole group and 41 patients to IV pantoprazole group. Both groups were similar for factors affecting the outcome. Bleeding reoccurred in five patients of omeprazole group and four patients in pantoprazole group [11.4% vs 9.8%]. The mean hospital stay and blood transfusion were not different in both groups. Oral omeprazole and IV pantoprazole had equal effects on prevention of rebleeding after endoscopic therapy in patients with high risk bleeding peptic ulcers

Bacillus claussi: en el tratamiento de erradicación del Helicobacter pylori: para reducir los síntomas adversos del tratamiento triple / Bacillus claussi: in the treatment of Helicobacter pylori eradication: to reduce the adverse symptoms of triple therapy

El tratamiento aceptado para la infección por Helicobacter pylori es el uso de inhibidores de bomba de protones (IBP), más dos antibióticos, siendo considerado de primera línea la amoxicilina y la claritromicina. Para el éxito del tratamiento es indispensable el cumplimiento dle mismo y es aquí donde el fracaso en la erradicación del Helicobacter pylori está relacionado al incumplimiento del tratamiento debido a los efectos adversos: náuseas, vómitos, diarrea y alteraciones del gusto. Para investigar la eficacia de la terapia triple para el Helicobacter pylori asociada a un probiótico ( Bacullus Claussi) se realizó un estudio prospectivo, con muestreo no probabilístico, intencional en 100 pacientes desde agosto de 2010 hasta febrero de 2011. Los pacientes fueron distribuidos en 2 grupos de 50 cada uno para recibir: grupo A. Esomeprazol, amoxicilina y claritromicina y grupo B; Esomeprazol, amoxicilina, claritromicina y Bacillus claussi. Se logró la erradicación del Helicobacter pylori en 96% de los pacientes del grupo B en comparación del 80% del grupo A (P = 0,027). El efecto adverso más importante fue la diarrea en el grupo A. La asociación de inhibidores de bomba de protones, antibióticos y Bacillus calussi aumentó el porcentaje de erradicación de Helicobacter pylori, evitando el abandono del tratamiento por la presencia de efectos adversos.

The consensus treatment for Helicobacter pylori infection is based on a Proton Pump Inhibitor plus two antibiotics being considered as first choice amoxicillin and clarithromycin. For a succesfull treatment is primordial its completion and here is where the failure on the Helicobacter pylori infection eradication is relationed to the non fulfillment because of its adverse effects: nauseas, vomiting, diarrhea and alterations of testing. In order to investigate the efficiency of triple therapy treatment associated to a probiotic (Bacillus claussi), its was made a prospective study with no probabilistic and intentional sampling in 100 patients since august, 2011 to february, 2011. Patients were distribuited in two groups of 50 each one, in order to receive the following treatment: Group A: Esomeprazole, amoxicillin and clarithromycin. Group B: Esomeprazole, amoxicillin, clarithromycin and Bacillus claussi. Eradications of helicobacter pylori infections was obtained in 96% of group patients, in comparation to 80% of group a patients (P = 0,027). The adverse effect most important was diarrhea on the group A. The association of PPI, antibiotics and Bacillus claussi improved the percentage of eradication of Helicobacter pylori infection, avoiding the give up of treatment because the presence of adverse effects.

Helicobacter pylori infection in India from a western perspective.

Helicobacter pylori is a common bacterial infectious disease whose manifestations predominately affect the gastrointestinal tract. India is the prototypical developing country as far as H. pylori infection is concerned and more than 20 million Indians are estimated to suffer from peptic ulcer disease. Considering the high level of Medicine and of the pharmaceutical industry, one would expect that India would be the source of much needed information regarding new therapies and approaches that remain effective in the presence of antimicrobial resistance, new methods to reliably prevent reinfection, and the development of therapeutic and preventive vaccines. Here, we discuss H. pylori as an Indian problem with an emphasis on H. pylori infection as a serious transmissible infectious disease. We discuss the pros and cons of eradication of H. pylori from the entire population and come down on the side of eradication. The available data from India regarding antimicrobial use and resistance as well as the effectiveness of various treatments is discussed. Rigorous ongoing studies to provide current regional antibiotic resistance patterns coupled with data concerning the success rate with different treatment regimens are needed to guide therapy. A systematic approach to identify reliably effective (e.g., 90% or greater treatment success) cost-effective regimens is suggested as well as details of regimens likely to be effective in India. H. pylori is just one of the health care problems faced in India, but one where all the resources are on hand to understand and solve it.